Treg cells play a central role in immune prevention and tolerance of aberrant immune responses. Treg-cell dysfunction happens in systemic autoimmune disorders as well as in chronic GVHD.12-14 There is considerable interest in ways of restore Treg cells in these disorders; these strategies are mainly focused on the adoptive transfer of Treg cells which have been purified and expanded ex vivo.29,30 In animal models of autoimmunity, Treg-cell improvement can reverse target-organ damage.31-33 In animal types of GVHD, adoptive transfer of Treg cells can prevent disease, but reversal of established inflammation remains uncertain.19 Unfortunately, Treg-cell isolation and large-scale expansion have been difficult to attain in humans, and measurable immune effects have been limited and brief.34,35 We evaluated the alternative strategy of preferential Treg-cell stimulation in vivo with the use of daily subcutaneous low-dose interleukin-2, documenting its feasibility and acceptable side-effect profile in individuals with dynamic chronic GVHD.I possibly could be younger. Doctors retiring early. Small methods bankrupted by up-front expenditures or locked into ineffective systems by the prohibitive cost of switching. Hours consumed by onerous data access unrelated to patient care. Workflow disruptions. And most importantly, massive intrusions on our individual relationships. These complaints could be dismissed as growing pains, born of resistance to improve. But transitional chaos should be distinguished from enduring harm.